Research ExplorerPublicationsSystemic bioavailability of estriol following single and rep...

Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.

Standard

Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. / Bühling, Kai J.; Eydeler, U; Borregaard, S; Schlegelmilch, R; Suesskind, M.

In: ARZNEIMITTEL-FORSCH, Vol. 62, No. 8, 8, 2012, p. 378-383.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bühling, KJ, Eydeler, U, Borregaard, S, Schlegelmilch, R & Suesskind, M 2012, 'Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.', ARZNEIMITTEL-FORSCH, vol. 62, no. 8, 8, pp. 378-383. <http://www.ncbi.nlm.nih.gov/pubmed/22692777?dopt=Citation>

APA

Bühling, K. J., Eydeler, U., Borregaard, S., Schlegelmilch, R., & Suesskind, M. (2012). Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. ARZNEIMITTEL-FORSCH, 62(8), 378-383. [8]. http://www.ncbi.nlm.nih.gov/pubmed/22692777?dopt=Citation

Vancouver

Bühling KJ, Eydeler U, Borregaard S, Schlegelmilch R, Suesskind M. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. ARZNEIMITTEL-FORSCH. 2012;62(8):378-383. 8.

Bibtex

@article{8ebcb832ed064844b218c0cbfa58ee8e,
title = "Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.",
abstract = "A prospective monocentric open-label and single-arm trial was performed in 19 postmenopausal women with diagnosed vaginal atrophy. The aim was to determine the extent of a systemic exposure to estriol (CAS 50-27-1). Administration of estriol containing pessaries was daily for 21 days. In order to establish a pharmacokinetic profile after single as well as multiple vaginal doses of 0.03 mg estriol blood samples were taken after the first vaginal administration as well as at day 21 after the last administration. Moreover, in order to control for accumulation additional blood samples were taken predose at days 6, 11 and 16.",
keywords = "Humans, Aged, Female, Middle Aged, Prospective Studies, Biological Availability, Administration, Intravaginal, Estriol/administration & dosage/adverse effects/*pharmacokinetics, *Pessaries, Humans, Aged, Female, Middle Aged, Prospective Studies, Biological Availability, Administration, Intravaginal, Estriol/administration & dosage/adverse effects/*pharmacokinetics, *Pessaries",
author = "B{\"u}hling, {Kai J.} and U Eydeler and S Borregaard and R Schlegelmilch and M Suesskind",
year = "2012",
language = "English",
volume = "62",
pages = "378--383",
number = "8",

}

RIS

TY - JOUR

T1 - Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries.

AU - Bühling, Kai J.

AU - Eydeler, U

AU - Borregaard, S

AU - Schlegelmilch, R

AU - Suesskind, M

PY - 2012

Y1 - 2012

N2 - A prospective monocentric open-label and single-arm trial was performed in 19 postmenopausal women with diagnosed vaginal atrophy. The aim was to determine the extent of a systemic exposure to estriol (CAS 50-27-1). Administration of estriol containing pessaries was daily for 21 days. In order to establish a pharmacokinetic profile after single as well as multiple vaginal doses of 0.03 mg estriol blood samples were taken after the first vaginal administration as well as at day 21 after the last administration. Moreover, in order to control for accumulation additional blood samples were taken predose at days 6, 11 and 16.

AB - A prospective monocentric open-label and single-arm trial was performed in 19 postmenopausal women with diagnosed vaginal atrophy. The aim was to determine the extent of a systemic exposure to estriol (CAS 50-27-1). Administration of estriol containing pessaries was daily for 21 days. In order to establish a pharmacokinetic profile after single as well as multiple vaginal doses of 0.03 mg estriol blood samples were taken after the first vaginal administration as well as at day 21 after the last administration. Moreover, in order to control for accumulation additional blood samples were taken predose at days 6, 11 and 16.

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Prospective Studies

KW - Biological Availability

KW - Administration, Intravaginal

KW - Estriol/administration & dosage/adverse effects/pharmacokinetics

KW - Pessaries

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Prospective Studies

KW - Biological Availability

KW - Administration, Intravaginal

KW - Estriol/administration & dosage/adverse effects/pharmacokinetics

KW - Pessaries

M3 - SCORING: Journal article

VL - 62

SP - 378

EP - 383

IS - 8

M1 - 8

ER -